Advertisement

Manufacturing of Biopharmaceutical APIs

  • John Geigert
Chapter

Abstract

The source material containing the genetic elements, coupled with the targeted design of a production/expression, harvest/isolation, and purification process, impacts the CMC regulatory compliance for the manufacture of the different biopharmaceutical APIs (also known as drug substance). The risk-based requirements and expectations for an adequate and appropriate control of the API manufacturing process, both upstream and downstream, across the lifecycle of the biopharmaceutical, are discussed. The advantages, and limitations, of the small-scale studies that are frequently used to characterize the API manufacturing process is presented.

Keywords

API Drug Substance Upstream Expression Systems Production Harvest Downstream Purification Genetic Stability Small-Scale Studies 

References

  1. 1.
    EMA European Public Assessment Report (EPAR): Semglee (Insulin Glargine, Biosimilar to Lantus) (January 2018); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004280/WC500249349.pdf
  2. 2.
    EMA European Public Assessment Report (EPAR): Abasria (Insulin Glargine) (June 2014); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002835/WC500175383.pdf
  3. 3.
    EMA European Public Assessment Report (EPAR): Inflixabi (Infliximab, Biosimilar to Remicade) (April 2016); www.ema.europa.eu/documents/assessment-report/flixabi-epar-public-assessment-report_en.pdf
  4. 4.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Flublok (Seasonal Flu Vaccine) – Package Insert (March 2017); www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM336020.pdf
  5. 5.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Cervarix (Human Papillomavirus Recombinant Vaccine) – Package Insert (2009); www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf
  6. 6.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Elelyso (Taliglucerase Alfa) – Package Insert (2016); www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf
  7. 7.
    Wurm, F. M. and Hacker, D., First CHO Genome; Nature Biotechnology (2011) 29: 718–720CrossRefGoogle Scholar
  8. 8.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: ATryn (Recombinant Antithrombin) – Package Insert (February 2009); www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM134045.pdf
  9. 9.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Ruconest (Recombinant C1 Esterase Inhibitor) – Package Insert (July 2014); www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM405634.pdf
  10. 10.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Kanuma (Sebelipase Alfa) – Package Insert (December 2015); www.accessdata.fda.gov/drugsatfda_docs/label/2015/125561s000lbl.pdf
  11. 11.
    FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data – Imlygic (Talimogene Laherparepvec) – Package Insert (2015); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469575.pdf
  12. 12.
    FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data – Luxturna (Voretigene Neparvovec-rzyl) – Package Insert (2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM589541.pdf
  13. 13.
    EMA European Public Assessment Report (EPAR): Glybera (Alipogene Tiparvovec) (July 2012); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002145/WC500135476.pdf
  14. 14.
    EMA European Public Assessment Report (EPAR): Lusduna (Biosimilar Insulin Glargine) (November 2016); http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004101/WC500219588.pdf
  15. 15.
    EMA European Public Assessment Report (EPAR): Vpriv (Velaglucerase Alfa) (September 2010); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001249/WC500096489.pdf
  16. 16.
    EMA European Public Assessment Report (EPAR): Qarziba (Dinutuximab Beta) (March 2017); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003918/WC500227726.pdf
  17. 17.
    FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data – Luxturna (Voretigene Neparvovec-rzyl) – Summary Basis for Regulatory Action (December 18, 2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM592083.pdf
  18. 18.
    World Health Organization (WHO) – Polio Global Erradication Initiative: Vaccine-Associated Paralytic Polio (VAPP) and Vaccine-Derived Poliovirus (VDPV) Fact Sheet (February 2015); www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/VAPPandcVDPVFactSheet-Feb2015.pdf
  19. 19.
    ICH Q5D ICH Q5D Derivation and Characterization of Cell Substrates Used For Production of Biotechnological/Biological Products (July 1997); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5D/Step4/Q5D_Guideline.pdf
  20. 20.
    EMA Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene Therapy Medicinal Products (March 22, 2018); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/07/WC500252056.pdf
  21. 21.
    ICH Q5A(R1) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin (September 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5A_R1/Step4/Q5A_R1__Guideline.pdf
  22. 22.
    FDA Draft Guidance for Industry: Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up (July 2018); www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610800.pdf
  23. 23.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Avastin (Bevacizumab): Approval History, Letters, Reviews and Related Documents – Chemistry Review (February 22, 2004); www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin_Chemr.pdf
  24. 24.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Perjeta (Pertuzumab): Approval History, Letters, Reviews and Related Documents – Statistical Review and Evaluation (June 5, 2012); www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125409Orig1s000StatR.pdf
  25. 25.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Perjeta (Pertuzumab): Approval History, Letters, Reviews and Related Documents – Cross Discipline Team Leader Review (June 08, 2012); www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125409Orig1s000CrossR.pdf
  26. 26.
    FDA Draft Guidance for Industry: Chemistry, Manufacturing and Controls Changes to an Approved Application – Certain Biological Products (December 2017); www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/general/ucm590118.pdf
  27. 27.
    WHO Guidelines on Procedures and Data Requirements for Changes to Approved Biotherapeutic Products (October 2017); www.who.int/biologicals/expert_committee/PAC_highlighted_20_Oct_2017.HK.IK.pdf?ua=1
  28. 28.
    EMA European Public Assessment Report (EPAR): Inflectra (Biosimilar Infliximab) (June 2013); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf
  29. 29.
    Rouiller, Y., Kleuser, B., et.al., Reciprocal Tranlocation Observed in End-og-Production Cells of a Commercial CHO-Based Process; PDA J Pharm Sci and Tech (2015) 69:540–552; PDA website, www.PDA.org
  30. 30.
    FDA Guidance For Industry: CGMP For Phase 1 Investigational Drugs (July 2008); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070273.pdf
  31. 31.
    EMA Guideline on the Requirements For Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials (September 2018); www.ema.europa.eu/documents/scientific-guideline/guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal_en-0.pdf
  32. 32.
    European Commission – EudraLex the Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice: Guidelines on Good Manufacturing Practice Specific to Advanced Therapy Medicinal Products (November 2017); ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf
  33. 33.
    CMC Biotech Working Group – A-Mab: A Case Study in Bioprocess Development (October 30, 2009); CASSS website, cdn.ymaws.com/www.casss.org/resource/resmgr/imported/A-Mab_Case_Study_Version_2-1.pdf
  34. 34.
    ICH M4Q(R1): Quality Overall Summary of Module 2, Module 3 Quality (September 2002); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4_R1_Quality/M4Q__R1_.pdf
  35. 35.
    FDA Guidance for Industry: For the Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody for In Vivo Use (August 1996); www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/general/ucm173477.pdf
  36. 36.
    EMA Guideline on Process Validation for the Manufacture of Biotechnology-Derived Active Substances and Data to be Provided in the Regulatory Submission (April 2016); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/04/WC500205447.pdf
  37. 37.
    ICH Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) (May 2012); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf
  38. 38.
    Pharmaceutical Inspection Co-operation Scheme (PIC/S): Aide-Memoires – Inspection of Biotechnology Manufactures (September 2007); PIC/S website; www.picscheme.org/en/publications
  39. 39.
    FDA Advisory Committee Meetings – Meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee: Spark Therapeutics, Luxturna (Voretigene Neparvovec-rzyl) – FDA Advisory Committee Briefing Document Prepared by Spark Therapeutics (October 12, 2017); www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM579300.pdf
  40. 40.
    Box, G. E. P., Robustness in the Strategy of Scientific Model Building, in Robustness in Statistics, edited by Launer, R. L. and Wilkinson, G. N., Academic Press , 201–236 (1979)
  41. 41.
    FDA Guidance for Industry: Process Validation – General Principles and Practices (January 2011); www.fda.gov/downloads/drugs/guidances/ucm070336.pdf
  42. 42.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Trulicity (Recombinant Dulaglutide): Approval History, Letters, Reviews and Related Documents – Chemistry Review (May 30, 2014); www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000ChemR.pdf
  43. 43.
    FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data – Andexxa (Recombinant Coagulation Factor Xa, Inactivated-zhzo) – Approval History, Letters, Reviews and Related Documents – October 27, 2016 Type A Meeting Summary (November 25, 2016); www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm606681.htm
  44. 44.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Lumizyme (Recombinant Alglucosidase Alfa): Approval History, Letters, Reviews and Related Documents – Chemistry Review – Resubmission of Lumizyme Manufactured at 4000L Bioreactor Scale (April 29, 2010); www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125291s000ChemR.pdf
  45. 45.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Perjeta (Pertuzumab): Approval History, Letters, Reviews and Related Documents – Chemistry Review (May 31, 2012); www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125409Orig1s000ChemR.pdf
  46. 46.
    Sarepta Therapeutics, Press Release – Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial Placed on Clinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events (May 25, 2018); Sarepta Therapeutics website – News Releases, www.sarepta.com
  47. 47.
    FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data – Kymriah (Tisagenlecleucel) – Package Insert (2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM573941.pdf
  48. 48.
    Baaj, A., Kaitin, K. I. and Serebrox, M., Manufacturing Strategy for Diverse Biologic Pipelines of the Future, Tuft Center for Study of Drug Development (October 2017); static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5aa2ff8953450a815ebf3377/1520631693367/Manufacturing-WP-2017.pdf

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • John Geigert
    • 1
  1. 1.BioPharmaceutical Quality SolutionsCarlsbadUSA

Personalised recommendations